US government appeals Gilead's trial win in Truvada, Descovy patent fight

As Gilead Sciences tussles with a web of HIV drug litigation, a high-stakes case tied to patents for prevention medicines is coming back to test the drugmaker.

On Friday, the U.S. Department of Justice appealed Gilead’s May 2023 victory in a Delaware court, which found that use of Gilead's pre-exposure prophylaxis (PrEP) regimens did not infringe three key patents the U.S. has credited to the CDC.